Literature DB >> 19818719

Silencing an immunodominant epitope of hepatitis B surface antigen reveals an alternative repertoire of CD8 T cell epitopes of this viral antigen.

Andreas Wieland1, Petra Riedl, Jörg Reimann, Reinhold Schirmbeck.   

Abstract

Immunodominance hierarchies operating in immune responses to viral antigens limit the diversity of the elicited T cell responses. The L(d)/S(28-39)-restricted CD8 T cell response to the hepatitis B surface antigen (HBsAg or S) prevents copriming of D(d)- and K(b)-restricted CD8 T cell responses. We exchanged L to V at position S(39) of HBsAg to construct mutant S(L39V). Comparable levels of wild-type S and mutant S(L39V) were produced by transiently transfected cells, and mice immunized with the pCI/S and pCI/S(L39V) DNA vaccines showed comparable serum antibody responses to HBsAg. The pCI/S but not pCI/S(L39V) DNA vaccination induced L(d)/S(28-39)-specific CD8 T cell responses. However, the pCI/S(L39V) DNA vaccine efficiently primed CD8 T cell responses to the subdominant D(d)- and K(b)-restricted epitopes, confirming the immunosuppressive phenotype of the L(d)/S(28-39)-specific CD8 T cell response. A single point mutation within the HBsAg can hence completely silence a 'dominant' CD8 T cell response thereby facilitating priming of a multispecific repertoire of suppressed, 'subdominant' epitopes. The data have practical implications for understanding HBV-specific CD8 T cell responses and for the design of novel vaccination strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818719     DOI: 10.1016/j.vaccine.2009.09.096

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Responses against a subdominant CD8+ T cell epitope protect against immunopathology caused by a dominant epitope.

Authors:  Tracy J Ruckwardt; Cindy Luongo; Allison M W Malloy; Jie Liu; Man Chen; Peter L Collins; Barney S Graham
Journal:  J Immunol       Date:  2010-09-10       Impact factor: 5.422

2.  Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection.

Authors:  Jamie F S Mann; Paul F McKay; Samantha Arokiasamy; Reeyeshkumar K Patel; Katja Klein; Robin J Shattock
Journal:  J Control Release       Date:  2013-06-14       Impact factor: 9.776

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.